Filing Details
- Accession Number:
- 0001144204-13-039039
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2013-07-10 21:33:20
- Reporting Period:
- 2013-07-08
- Filing Date:
- 2013-07-10
- Accepted Time:
- 2013-07-10 21:33:20
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1270073 | Intercept Pharmaceuticals Inc | ICPT | Pharmaceutical Preparations (2834) | 223868459 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1353128 | Gayle Barbara Duncan | C/O Intercept Pharmaceuticals, Inc. 18 Desbrosses Street New York NY 10013 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2013-07-08 | 25,000 | $9.82 | 33,112 | No | 4 | M | Direct | |
Common Stock | Disposition | 2013-07-08 | 25,000 | $45.39 | 8,112 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Options to Purchase Common Stock | Disposition | 2013-07-08 | 25,000 | $0.00 | 25,000 | $9.82 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
19,520 | 2019-05-18 | No | 4 | M | Direct |
Footnotes
- The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 20, 2013.
- All shares underlying this option have fully vested.
- This transaction was executed in multiple trades at prices ranging from $45.0901 to $45.6902. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.